Hanna R. Rosenheck

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer”.

Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer

npj Breast Cancer(2025)10.1038/s41523-025-00767-2

N/A

0.312DataRank · unranked

5 citations

Emily Schultz, Jianxin Wang, Hanna R. Rosenheck, Sidney Mahan, Erik S. Knudsen +2 more

CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities

Cell Reports(2022)10.1016/j.celrep.2022.110448

N/A

0DataRank · unranked

134 citations

Vishnu Kumarasamy, Ram Nambiar, Joel D. Pearson, Paris Vail, Hanna R. Rosenheck +8 more

Galectin-3 expression in donor T cells reduces GvHD severity and lethality after allogeneic hematopoietic cell transplantation

Cell Reports(2023)10.1016/j.celrep.2023.112250

N/A

0DataRank · unranked

10 citations

Takemasa Tsuji, Cameron R. MacDonald, Joseph L. Sarow, Hanna R. Rosenheck, Saeed Daneshmandi +10 more

Pharmacologically targeting KRAS G12D in PDAC models: tumor cell intrinsic and extrinsic impact

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.03.18.533261

N/A

0DataRank · unranked

3 citations

Costakis Frangou, Jianxin Wang, Yin Wan, Andrew Dynka, Hanna R. Rosenheck +5 more

The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer

Cancer Research(2024)10.1158/0008-5472.can-23-2504

N/A

0DataRank · unranked

48 citations

Jianxin Wang, Costakis Frangou, Yin Wan, Andrew Dynka, Hanna R. Rosenheck +5 more

Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle

Nature Communications(2025)10.1038/s41467-025-56674-4

N/A

0DataRank · unranked

35 citations

Jianxin Wang, Michelle Roti, Yin Wan, Adam P. Dommer, Hanna R. Rosenheck +11 more